Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 How heterogeneous are gliomas?

× No keyword cloud information.

8 in total

1. A cerebral glioma model for experimental therapy and in vivo invasion studies in syngeneic BD IX rats.

Authors: O Mella; R Bjerkvig; B C Schem; O Dahl; O D Laerum
Journal: J Neurooncol Date: 1990-10 Impact factor: 4.130

2. An isotope agarose assay for rapid testing of the sensitivity of glioma biopsies to chemotherapeutic drugs and biological response modifiers. Effects of BCNU, vincristine, lymphokines and the recombinant agents interferon alpha 2c, interferon gamma and tumour necrosis factor.

Authors: G Unsgaard; E Helseth; R Vik; A Dalen
Journal: Acta Neurochir (Wien) Date: 1988 Impact factor: 2.216

3. Effects of combination chemotherapy with biscoclaurine-derived alkaloid (Cepharanthine) and nimustine hydrochloride on malignant glioma cell lines.

Authors: Katsuhiko Kono; Jun A Takahashi; Tetsuya Ueba; Hisae Mori; Nobuo Hashimoto; Manabu Fukumoto
Journal: J Neurooncol Date: 2002-01 Impact factor: 4.130

Review 4. Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma.

Authors: John H Sampson; Gary E Archer; Duane A Mitchell; Amy B Heimberger; Darell D Bigner
Journal: Semin Immunol Date: 2008-06-09 Impact factor: 11.130

5. Effects of type beta transforming growth factor in combination with retinoic acid or tumor necrosis factor on proliferation of a human glioblastoma cell line and clonogenic cells from freshly resected human brain tumors.

Authors: E Helseth; G Unsgaard; A Dalen; R Vik
Journal: Cancer Immunol Immunother Date: 1988 Impact factor: 6.968

How heterogeneous are gliomas?

1. A cerebral glioma model for experimental therapy and in vivo invasion studies in syngeneic BD IX rats.

2. An isotope agarose assay for rapid testing of the sensitivity of glioma biopsies to chemotherapeutic drugs and biological response modifiers. Effects of BCNU, vincristine, lymphokines and the recombinant agents interferon alpha 2c, interferon gamma and tumour necrosis factor.

3. Effects of combination chemotherapy with biscoclaurine-derived alkaloid (Cepharanthine) and nimustine hydrochloride on malignant glioma cell lines.

Review 4. Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma.

5. Effects of type beta transforming growth factor in combination with retinoic acid or tumor necrosis factor on proliferation of a human glioblastoma cell line and clonogenic cells from freshly resected human brain tumors.

6. A quantitative study of blood-brain barrier permeability ultrastructure in a new rat glioma model.

Review 7. EGFRvIII-targeted vaccination therapy of malignant glioma.

8. Intravenous BCNU and AZQ in patients with recurrent malignant gliomas.